Journal Scans
A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
Gefitinib Is Active in Cutaneous Squamous Cell Carcinoma
CM Lewis, BS Glisson, L Feng, RS Weber, et al
20120018
2012 Jan 18
Clin Cancer Res
A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
Clin Cancer Res. 2012 Jan 18;[Epub Ahead of Print], CM Lewis, BS Glisson, L Feng, RS Weber, et al
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
More than 90% of cases of cutaneous squamous cell carcinoma (CSCC) are cured by standard initial treatment, but having even one risk factor lowers 3-year disease-specific survival by 30%. Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has produced clinical benefits in other squamous cell carcinomas and shown antitumor activity in preclinical studies in CSCC. The current phase II study evaluated the efficacy of neoadjuvant gefitinib in patients with high-risk...
